entity,start_date,end_date,context,AARSRAPPORT_html,AARSRAPPORT_pdf,AARSRAPPORT_xml,AddressOfAuditorDistrictName,AddressOfAuditorPostCodeIdentifier,AddressOfAuditorStreetBuildingIdentifier,AddressOfAuditorStreetName,AddressOfFinancialDistrictName,AddressOfFinancialPostCodeIdentifier,AddressOfFinancialStreetBuildingIdentifier,AddressOfFinancialStreetName,AddressOfLawFirmDistrictName,AddressOfLawFirmPostCodeIdentifier,AddressOfLawFirmStreetBuildingIdentifier,AddressOfLawFirmStreetName,AddressOfReportingEntityDistrictName,AddressOfReportingEntityPostCodeIdentifier,AddressOfReportingEntityStreetBuildingIdentifier,AddressOfReportingEntityStreetName,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,AdministrativeExpenses,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,CostOfSales,DateOfApprovalOfAnnualReport,DateOfGeneralMeeting,DescriptionMethodsOfRecognitionAndMeasurementBasisForCashFlowsStatement,DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies,DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities,DescriptionOfMethodsOfPrepayments,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeLiabilities,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDistributionCosts,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInventories,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfProvisions,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax,DescriptionOfMethodsOfStatingKeyFiguresAndFinancialRatiosIncludedInManagementReview,DescriptionOfMethodsOfTranslationOfForeignCurrencies,DisclosureOfContingentLiabilities,DisclosureOfContributedCapital,DisclosureOfDeferredTaxAssetsAndLiabilities,DisclosureOfEmployeeBenefitsExpense,DisclosureOfOtherFinanceExpenses,DisclosureOfOtherFinanceIncome,DisclosureOfOtherProvisions,DisclosureOfPropertyPlantAndEquipment,DisclosureOfTaxExpenses,DistributionCosts,GrossResult,IdentificationNumberCvrOfAuditFirm,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationOfApprovedAnnualReport,IdentificationOfAuditedFinancialStatements,IndependentAuditorsReportsAudit,InformationOnCalculationOfKeyFiguresAndFinancialRatios,InformationOnConsolidatedFinancialStatements,InformationOnRelatedEntities,InformationOnReportingClassOfEntity,InformationOnSegments,InformationOnTypeOfSubmittedReport,ManagementsReview,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfAuditFirm,NameOfFinancialInstitution,NameOfLawFirm,NameOfReportingEntity,NameOfSubmittingEnterprise,OpinionOnAuditedFinancialStatements,OtherFinanceExpenses,OtherFinanceIncome,PlaceOfSignatureOfStatement,ProfitLoss,ProfitLossFromOrdinaryActivitiesBeforeTax,ProfitLossFromOrdinaryOperatingActivities,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,Revenue,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,StatementByExecutiveAndSupervisoryBoards,StatementOfAuditorsResponsibilityForAuditAndAuditPerformed,StatementOfChangesInEquity,StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements,StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements,TaxExpense,TitleOfMemberOfExecutiveBoard,TitleOfMemberOfSupervisoryBoard,TypeOfAuditorAssistance,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,CurrentDeferredTaxAssets,DepositsLongtermInvestmentsAndReceivables,Equity,FixturesFittingsToolsAndEquipment,Inventories,LeaseholdImprovements,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,LongtermInvestmentsAndReceivables,NoncurrentAssets,OtherProvisions,OtherShorttermPayables,OtherShorttermReceivables,PropertyPlantAndEquipment,ProposedDividendRecognisedInEquity,Provisions,ProvisionsForDeferredTax,RetainedEarnings,ShorttermDeferredIncome,ShorttermLiabilitiesOtherThanProvisions,ShorttermPayablesToGroupEnterprises,ShorttermPrepaymentsReceivedFromCustomers,ShorttermReceivables,ShorttermReceivablesFromGroupEnterprises,ShorttermTaxPayables,ShorttermTradePayables,ShorttermTradeReceivables,AverageNumberOfEmployees,GrossMargin,GrossProfitLoss,InvestmentInPropertyPlantAndEquipment,ResultsFromNetFinancials,ReturnOnCapitalEmployed,ReturnOnEquity,SolvencyRatio,NameOfKeyFigureOrFinancialRatio,ValueOfKeyFigureOrFinancialRatio,NameAndSurnameOfMemberOfSupervisoryBoard,DescriptionOfAuditor,NameAndSurnameOfAuditor
29476012,2013-10-01,2014-09-30,ctx22,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",3298622.0,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",182267830.0,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",16260728.0,45728954.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",1697637.0,1836157.0,Herlev,19812517.0,26308124.0,26169604.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,227996784.0,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",6495607.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2013-10-01,2014-09-30,ctx24,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,55011492.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2013-10-01,2014-09-30,ctx26,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,-20000000.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2014-09-30,2014-09-30,ctx27,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,183720598.0,29983732.0,750000.0,181778243.0,256250.0,301013.0,55761492.0,837868.0,68593832.0,803474.0,183720598.0,121691501.0,301013.0,1942355.0,6267605.0,29782142.0,369132.0,1641342.0,20000000.0,6267605.0,0.0,35011492.0,27389096.0,121691501.0,29470032.0,28862458.0,83200679.0,6364164.0,5621761.0,566012.0,76211133.0,,,,,,,,,,,,,
29476012,2014-10-01,2015-09-30,ctx1,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",3640903.0,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",186859542.0,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",16397911.0,42434153.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",306179.0,5560116.0,Herlev,21139963.0,27649276.0,22395339.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,229293695.0,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",6509313.0,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38.0,0.185,42434000.0,689000.0,5254000.0,0.082,0.375,0.209,,,,,
29476012,2014-10-01,2015-09-30,ctx10,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,12303000.0,,12604000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,289320000.0,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37.0,0.117,33708000.0,178000.0,3888000.0,0.088,0.284,0.344,,,,,
29476012,2014-10-01,2015-09-30,ctx11,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,7648000.0,,13003000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,182106000.0,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38.0,0.166,30189000.0,434000.0,-2517000.0,0.065,0.205,0.187,,,,,
29476012,2014-10-01,2015-09-30,ctx17,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin %,98.0,,,
29476012,2014-10-01,2015-09-30,ctx18,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin %,115.0,,,
29476012,2014-10-01,2015-09-30,ctx19,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin %,121.0,,,
29476012,2014-10-01,2015-09-30,ctx2,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2014-10-01,2015-09-30,ctx20,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin %,44.0,,,
29476012,2014-10-01,2015-09-30,ctx21,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin %,71.0,,,
29476012,2014-10-01,2015-09-30,ctx23,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,56151455.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2014-10-01,2015-09-30,ctx25,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,-8000000.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2014-10-01,2015-09-30,ctx3,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Michael Sandhu,,
29476012,2014-10-01,2015-09-30,ctx4,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JÃ¸rgen Kjergaard Madsen,,
29476012,2014-10-01,2015-09-30,ctx5,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vagn Thorup,,
29476012,2014-10-01,2015-09-30,ctx6,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,State Authorised Public Accountant,Jesper Wiinholt
29476012,2014-10-01,2015-09-30,ctx7,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,State Authorised Public Accountant,Jens Michael Colstrup
29476012,2014-10-01,2015-09-30,ctx8,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,19813000.0,,26170000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,227997000.0,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37.0,0.201,45729000.0,1375000.0,139000.0,0.142,0.406,0.304,,,,,
29476012,2014-10-01,2015-09-30,ctx9,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,18101000.0,,26135000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,215153000.0,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36.0,0.209,45049000.0,577000.0,2073000.0,0.183,0.396,0.294,,,,,
29476012,2015-09-30,2015-09-30,ctx12,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,271759983.0,91353645.0,750000.0,269789620.0,0.0,308538.0,56901455.0,1033732.0,52022957.0,628093.0,271759983.0,207616973.0,308538.0,1970363.0,6799222.0,34880445.0,84286335.0,1661825.0,8000000.0,7241555.0,442333.0,48151455.0,22554233.0,207616973.0,28730516.0,116112569.0,126413018.0,11364094.0,4574385.0,764825.0,30762589.0,,,,,,,,,,,,,
29476012,2015-09-30,2015-09-30,ctx13,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,183721000.0,,,,,,55761000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2015-09-30,2015-09-30,ctx14,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,142524000.0,,,,,,41949000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2015-09-30,2015-09-30,ctx15,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,143885000.0,,,,,,49448000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2015-09-30,2015-09-30,ctx16,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ0L2Q4LzFlLzUwL2MyMGMtNDVlYS1hMTcyLTYyMTljN2Y1MWY5Mg.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzQ5LzFiL2ZmLzZmL2JiYmMtNDQ4My1hZDAwLWY0ZjIyNGUyYWMyNA.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,DK-2730,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen  44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia AS</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2015</td></tr><tr><td colspan=""1"">of the Company operations for 2014/2015.</td></tr></table>",,2016-02-29,2016-02-29,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been</td></tr><tr><td colspan=""1"">prepared as the cash flow statement is included in the Consolidated Financial Statements of the Compa-</td></tr><tr><td colspan=""1"">nyâs Parent Company.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial</td></tr><tr><td colspan=""1"">assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses in-</td></tr><tr><td colspan=""1"">curred to achieve the earnings for the year are recognised in the income statement, including depreciation,</td></tr><tr><td colspan=""1"">amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates</td></tr><tr><td colspan=""1"">of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to</td></tr><tr><td colspan=""1"">the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow</td></tr><tr><td colspan=""1"">out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as</td></tr><tr><td colspan=""1"">described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a</td></tr><tr><td colspan=""1"">constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less</td></tr><tr><td colspan=""1"">any repayments and with addition/deduction of the cumulative amortisation of any difference between</td></tr><tr><td colspan=""1"">cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment,</td></tr><tr><td colspan=""1"">while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typi-</td></tr><tr><td colspan=""1"">cally prepaid rent, insurance premiums, subscriptions, etc as well as fair value adjustments of derivative</td></tr><tr><td colspan=""1"">financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and</td></tr><tr><td colspan=""1"">costs of transportation to the place of business as well as expenses for installations and guarantee services.</td></tr><tr><td colspan=""1"">Direct delivery charges and expenses for training of customers in the application of the equipment are</td></tr><tr><td colspan=""1"">also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years</td></tr><tr><td colspan=""1"">and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related</td></tr><tr><td colspan=""1"">to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend ex-</td></tr><tr><td colspan=""1"">pected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">are measured under the FIFO principle at cost with addition of costs of transportation to the</td></tr><tr><td colspan=""1"">place of business. Considering the date of acquisition, write-down has been made to meet losses due to</td></tr><tr><td colspan=""1"">technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""2"">Property, plant and equipment</td></tr><tr><td colspan=""2"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is</td></tr><tr><td colspan=""2"">made on a straight line basis as follows</td></tr><tr><td>Fixtures, fittings, tools and equipment</td><td>3-5 years</td></tr><tr><td>IT-equipment</td><td>3 years</td></tr><tr><td>Leasehold improvements</td><td>5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date</td></tr><tr><td colspan=""1"">- the Company has a legal or constructive obligation and it is probable that economic benefits must be</td></tr><tr><td colspan=""1"">given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td colspan=""1"">which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td colspan=""1"">mined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a</td></tr><tr><td colspan=""1"">general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">is recognised in the income statement when the sale is considered effected based on the follow-</td></tr><tr><td colspan=""1"">ing criteria</td></tr><tr><td colspan=""1"">delivery has been made before year end;</td></tr><tr><td colspan=""1"">a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">the sales price has been determined and</td></tr><tr><td colspan=""1"">payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to</td></tr><tr><td colspan=""1"">the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries</td></tr><tr><td colspan=""1"">is recognised directly in equity. Any share of the tax reported in the income statement arising from prof-</td></tr><tr><td colspan=""1"">it/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share</td></tr><tr><td colspan=""1"">is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is cal-</td></tr><tr><td colspan=""1"">culated at the tax rate which, based on legislation passed before the end of the financial year, will apply at</td></tr><tr><td colspan=""1"">the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society</td></tr><tr><td colspan=""1"">of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = Gross profit x 100 / Revenue</td></tr><tr><td colspan=""1"">Profit margin = Profit before financiels x 100 / Revenue</td></tr><tr><td colspan=""1"">Return on net assets = Profit before financials x 100 / Total assets</td></tr><tr><td colspan=""1"">Solvency ratio = Equity at year - end x 100 / Total assets</td></tr><tr><td colspan=""1"">Return on equity = Net profit for the year x 100 / (Equity at year - end + Equity at year start)/2</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains</td></tr><tr><td colspan=""1"">and losses arising due to differences between the transaction date rates and the rates at the dates of pay-</td></tr><tr><td colspan=""1"">ment are recognized in financial income and expenses in the income statement. Where foreign exchange</td></tr><tr><td colspan=""1"">transactions are considered hedging of future cash flows, the value adjustments are recognized directly in</td></tr><tr><td colspan=""1"">equity.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of ex-</td></tr><tr><td colspan=""1"">change on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Contingent liabilities and security</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2018.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 4.486 of which kDKK 1.349 falls due within 1 year</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >and kDKK 3.137 falls due within 1-5 years.</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 150.911</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof. No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""24%"" align=""center"" valign=""middle"" >256250</td><td width=""17%"" align=""right"" valign=""middle"" >58209</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, tax-year 2014</td><td width=""24%"" align=""center"" valign=""middle"" >-17628</td><td width=""17%"" align=""right"" valign=""middle"" >-2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""24%"" align=""center"" valign=""middle"" >-680955</td><td width=""17%"" align=""right"" valign=""middle"" >200416</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >-442333</td><td width=""17%"" align=""right"" valign=""middle"" >256250</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Notes to the Annual Report</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >2014/2015</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >2013/2014</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""16%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""22%"" align=""right"" valign=""middle"" >32051667</td><td width=""16%"" align=""right"" valign=""middle"" >33146160</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""22%"" align=""right"" valign=""middle"" >3557049</td><td width=""16%"" align=""right"" valign=""middle"" >3385754</td></tr><tr><td width=""8%"" ></td><td width=""54%"" ></td><td width=""22%"" align=""right"" valign=""middle"" >35608716</td><td width=""16%"" align=""right"" valign=""middle"" >36531914</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >""Administation and sundry indirect expenses"" in the Income Statement.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Executive Board is not stated.</td></tr><tr><td width=""8%"" ></td><td width=""92%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""8%"" ></td><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""22%"" align=""right"" valign=""middle"" >38</td><td width=""16%"" align=""right"" valign=""middle"" >37</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""24%"" align=""right"" valign=""middle"" >1989</td><td width=""17%"" align=""right"" valign=""middle"" >127</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""24%"" align=""right"" valign=""middle"" >304190</td><td width=""17%"" align=""right"" valign=""middle"" >1697510</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >306179</td><td width=""17%"" align=""right"" valign=""middle"" >1697637</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""24%"" align=""right"" valign=""middle"" >79432</td><td width=""17%"" align=""right"" valign=""middle"" >116802</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""24%"" align=""right"" valign=""middle"" >5480684</td><td width=""17%"" align=""right"" valign=""middle"" >1719355</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >5560116</td><td width=""17%"" align=""right"" valign=""middle"" >1836157</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""24%"" align=""center"" valign=""middle"" >6799222</td><td width=""17%"" align=""right"" valign=""middle"" >6267605</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures,</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >fittings, tools and</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >equipment</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >improvements</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >3791215</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >847403</td><td width=""10%"" align=""right"" valign=""middle"" >4652038</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""20%"" align=""right"" valign=""middle"" >621314</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >67422</td><td width=""10%"" align=""right"" valign=""middle"" >688736</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""20%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >4412529</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >914825</td><td width=""10%"" align=""right"" valign=""middle"" >5340774</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 1 October</td><td width=""20%"" align=""right"" valign=""middle"" >2953347</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >43929</td><td width=""10%"" align=""right"" valign=""middle"" >3010696</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""20%"" align=""right"" valign=""middle"" >425450</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >242803</td><td width=""10%"" align=""right"" valign=""middle"" >668253</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Reversal of depreciation of</td></tr><tr><td width=""69%"" colspan=""2"" align=""left"" valign=""middle"" >disposals for the year</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Depreciation and</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >impairment</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >at 30 September</td><td width=""20%"" align=""right"" valign=""middle"" >3378797</td><td width=""13%"" align=""right"" valign=""middle"" >13420</td><td width=""8%"" align=""right"" valign=""middle"" >286732</td><td width=""10%"" align=""right"" valign=""middle"" >3678949</td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Carrying amount at 30</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >September</td><td width=""20%"" align=""right"" valign=""middle"" >1033732</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""8%"" align=""right"" valign=""middle"" >628093</td><td width=""10%"" align=""right"" valign=""middle"" >1661825</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3 -5 Ã¥r</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement:</td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""20%"" align=""right"" valign=""middle"" >577510</td><td width=""13%"" align=""right"" valign=""middle"" >384744</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""20%"" align=""right"" valign=""middle"" >51873</td><td width=""13%"" align=""right"" valign=""middle"" >31274</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""20%"" align=""right"" valign=""middle"" >38870</td><td width=""13%"" align=""right"" valign=""middle"" >38787</td><td width=""8%"" ></td><td width=""10%"" ></td></tr><tr><td width=""49%"" ></td><td width=""20%"" align=""right"" valign=""middle"" >668253</td><td width=""13%"" align=""right"" valign=""middle"" >454805</td><td width=""8%"" ></td><td width=""10%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""24%"" align=""right"" valign=""middle"" >36615</td><td width=""17%"" align=""right"" valign=""middle"" >6912</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""24%"" align=""right"" valign=""middle"" >5774115</td><td width=""17%"" align=""right"" valign=""middle"" >6686736</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax previous years</td><td width=""24%"" align=""right"" valign=""middle"" >17628</td><td width=""17%"" align=""right"" valign=""middle"" >2375</td></tr><tr><td width=""59%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""24%"" align=""right"" valign=""middle"" >680955</td><td width=""17%"" align=""right"" valign=""middle"" >-200416</td></tr><tr><td width=""59%"" ></td><td width=""24%"" align=""right"" valign=""middle"" >6509313</td><td width=""17%"" align=""right"" valign=""middle"" >6495607</td></tr><tr><td colspan=""3""></td></tr></table>",,,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian</td></tr><tr><td colspan=""1"">Medical Systems Scandinavia AS for the financial year 2014/2015.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Report on the Financial Statements</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia AS for the financial</td></tr><tr><td colspan=""1"">year 1 October 2014 â 30 September 2015, which comprise income statement, balance sheet, statement of</td></tr><tr><td colspan=""1"">chances in equity, notes and summary of significant accounting policies. The Financial Statements are</td></tr><tr><td colspan=""1"">prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period, the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions, see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" ><b>The Group</b></td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td colspan=""1""></td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Controlling interest  </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""70%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Varian Medical Systems International Holdings Inc. </b></td><td width=""30%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >duties in the Company.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td colspan=""2""></td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >transactions with the Supervisory Board, the Executive Board, senior employees, significant</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >shareholders, group enterprises or other related parties, except for normal management</td></tr><tr><td width=""100%"" colspan=""2"" align=""left"" valign=""middle"" >remuneration and fee for legal advisory services.</td></tr><tr><td colspan=""2""></td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" ><b>Related parties and ownership</b></td></tr><tr><td width=""54%"" ></td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Country</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""54%"" ></td><td width=""22%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >USA</td><td width=""14%"" align=""right"" valign=""middle"" >87020</td><td width=""10%"" align=""right"" valign=""middle"" >3715</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""14%"" align=""right"" valign=""middle"" >11982</td><td width=""10%"" align=""right"" valign=""middle"" >984</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""14%"" align=""right"" valign=""middle"" >46204</td><td width=""10%"" align=""right"" valign=""middle"" >5609</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""14%"" align=""right"" valign=""middle"" >340</td><td width=""10%"" align=""right"" valign=""middle"" >125</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""14%"" align=""right"" valign=""middle"" >8</td><td width=""10%"" align=""right"" valign=""middle"" >5</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >1207</td><td width=""10%"" align=""right"" valign=""middle"" >1631</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""14%"" align=""right"" valign=""middle"" >348</td><td width=""10%"" align=""right"" valign=""middle"" >880</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""14%"" align=""right"" valign=""middle"" >21</td><td width=""10%"" align=""right"" valign=""middle"" >37</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""14%"" align=""right"" valign=""middle"" >31</td><td width=""10%"" align=""right"" valign=""middle"" >212</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""14%"" align=""right"" valign=""middle"" >83720</td><td width=""10%"" align=""right"" valign=""middle"" >507</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""14%"" align=""right"" valign=""middle"" >380</td><td width=""10%"" align=""right"" valign=""middle"" >142</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""14%"" align=""right"" valign=""middle"" >2</td><td width=""10%"" align=""right"" valign=""middle"" >1503</td></tr><tr><td width=""54%"" colspan=""1"" align=""left"" valign=""middle"" >VMS K.K.</td><td width=""22%"" colspan=""1"" align=""right"" valign=""middle"" >Japan</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >431</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for VarÃ­an Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >as holding at least 5% of the votes or at least 5% of the share capital:</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2014 â</td></tr><tr><td colspan=""1"">30 September 2015 has been prepared in accordance with the provisions of the Danish Financial State-</td></tr><tr><td colspan=""1"">ments Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland.</td></tr><tr><td colspan=""1"">The business is run from rented premised at Herlev. The company has a permanent establishment in Swe-</td></tr><tr><td colspan=""1"">den.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory.</td></tr><tr><td colspan=""1"">The result for the year was a profit of DKK 21,139,963 against DKK 19,812,517 in 2013/2014. The result</td></tr><tr><td colspan=""1"">for the year is positively affected by the trends in exchange rates.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material</td></tr><tr><td colspan=""1"">influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2015/2016 will end lower than reported for</td></tr><tr><td colspan=""1"">the financial year 2014/2015.</td></tr><tr><td colspan=""1"">The company has signed a contract for the supply of equipment and services to the Danish Centre for Par-</td></tr><tr><td colspan=""1"">ticle Therapy in Aarhus in 2017 and thus expects increased activity in the long run.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 140 million at Danske Bank is guaranteed by the Companyâs Parent Com-</td></tr><tr><td colspan=""1"">pany.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly pub-</td></tr><tr><td colspan=""1"">lic hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of</td></tr><tr><td colspan=""1"">importance to the results. The Company does not hedge the currency positions.</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan=""1"">at 30 September 2015 and of the results of the Company operations for the financial year 1 October 2014</td></tr><tr><td colspan=""1"">- 30 September 2015 in accordance with the Danish Financial Statements Act.</td></tr></table>",,,Herlev,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2015-09-30,2014-10-01,,2016-02-29,Copenhagen,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibility</td></tr><tr><td colspan=""1"">Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted</td></tr><tr><td colspan=""1"">our audit in accordance with International Standards on Auditing and additional requirements under Dan-</td></tr><tr><td colspan=""1"">ish audit regulation. This requires that we comply with ethical requirements and plan and perform the au-</td></tr><tr><td colspan=""1"">dit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.</td></tr><tr><td colspan=""1"">An audit involves performing audit procedures to obtain audit evidence about the amounts and disclo-</td></tr><tr><td colspan=""1"">sures in the Financial Statements. The procedures selected depend on the auditorâs judgment, including</td></tr><tr><td colspan=""1"">the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or</td></tr><tr><td colspan=""1"">error.</td></tr><tr><td colspan=""1"">In making those risk assessments, the auditor considers internal control relevant to the Companyâs prepa-</td></tr><tr><td colspan=""1"">ration of Financial Statements that give a true and fair view in order to design audit procedures that are</td></tr><tr><td colspan=""1"">appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of</td></tr><tr><td colspan=""1"">the Companyâs internal control. An audit also includes evaluating the appropriateness of accounting poli-</td></tr><tr><td colspan=""1"">cies used and the reasonableness of accounting estimates made by Management, as well as evaluating the</td></tr><tr><td colspan=""1"">overall presentation of the Financial Statements.</td></tr><tr><td colspan=""1"">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for</td></tr><tr><td colspan=""1"">our audit opinion.</td></tr><tr><td colspan=""1"">The audit has not resulted in any qualification.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" ><b>Statement of Changes in Equity</b></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" ></td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" ></td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >dividend for</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >earnings</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >the year</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""45%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""13%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""14%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""18%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 1 October </b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>35011492</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>20000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>55761492</b></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >750000</td><td width=""13%"" align=""right"" valign=""middle"" >35011492</td><td width=""14%"" align=""right"" valign=""middle"" >20000000</td><td width=""18%"" align=""right"" valign=""middle"" >55761492</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >0</td><td width=""14%"" align=""right"" valign=""middle"" >-20000000</td><td width=""18%"" align=""right"" valign=""middle"" >-20000000</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >21139963</td><td width=""14%"" align=""right"" valign=""middle"" >0</td><td width=""18%"" align=""right"" valign=""middle"" >21139963</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""10%"" align=""right"" valign=""middle"" >0</td><td width=""13%"" align=""right"" valign=""middle"" >-8000000</td><td width=""14%"" align=""right"" valign=""middle"" >8000000</td><td width=""18%"" align=""right"" valign=""middle"" >0</td></tr><tr><td colspan=""5""></td></tr><tr><td width=""45%"" colspan=""1"" align=""left"" valign=""middle"" ><b>Equity at 30 September</b></td><td width=""10%"" align=""right"" valign=""middle"" ><b>750000</b></td><td width=""13%"" align=""right"" valign=""middle"" ><b>48151455</b></td><td width=""14%"" align=""right"" valign=""middle"" ><b>8000000</b></td><td width=""18%"" align=""right"" valign=""middle"" ><b>56901455</b></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibility for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in</td></tr><tr><td colspan=""1"">accordance with the Danish Financial Statements Act, and for such internal control as Management de-</td></tr><tr><td colspan=""1"">termines is necessary to enable the preparation of Financial Statements that are free from material mis-</td></tr><tr><td colspan=""1"">statement, whether due to fraud or error.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Statement on Managementâs Review</td></tr><tr><td colspan=""1"">We have read Managementâs Review in accordance with the Danish Financial Statements Act. We have</td></tr><tr><td colspan=""1"">not performed any procedures additional to the audit of the Financial Statements. On this basis, in our</td></tr><tr><td colspan=""1"">opinion, the information provided in Managementâs Review is consistent with the Financial Statements.</td></tr></table>",,CEO,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:22091234,indberetninger-20180424,2.5097403999999996,29476012.0,,2018-03-29T03:11:55.135Z,2016-03-11T13:41:33.032Z,regnskab,0.0,,2015-09-30,2014-10-01,X16-AS-02-HL,2016-03-11T13:41:33.466Z,199081000.0,,,,,,37144000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
